Extent of disease based on initial bone scan: Important prognostic predictor for patients with metastatic prostatic cancer: Experience from the Scandinavian Prostatic Cancer Group Study No. 2 (SPCG-2)

European Urology

Volumn 28, Issue 1, 1995, Pages 40-46

  Jorgensen, T ^a   Muller, C ^a   Kaalhus, O ^a   Danielsen, H E ^a   Tveter, K J ^a  

^a OSLO UNIVERSITY HOSPITAL   (Norway)

Author keywords

Bone scintigrams; Metastatic prostatic cancer, extent of disease; Total androgen suppression

Indexed keywords

ANTIANDROGEN; CYPROTERONE ACETATE; MEDRONATE TECHNETIUM TC 99M; RADIOPHARMACEUTICAL AGENT;

ARTICLE; BONE METASTASIS; BONE SCINTISCANNING; CANCER CHEMOTHERAPY; CANCER SCINTISCANNING; CANCER SURGERY; CANCER SURVIVAL; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; HUMAN; INTRAVENOUS DRUG ADMINISTRATION; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; ORCHIECTOMY; PREDICTION; PRIORITY JOURNAL; PROGNOSIS; PROSTATE CANCER; RANDOMIZED CONTROLLED TRIAL;

EID: 0029024567     PISSN: 03022838     EISSN: None     Source Type: Journal    
DOI: 10.1159/000475018     Document Type: Article

References (0)